Accessibility Menu
Immix Biopharma logo

Immix Biopharma(NASDAQ) IMMX

Market Cap$608.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+133%
5 YearN/A
1 Year+211%
1 Month-17%
$8.34
-2.46%
-0.21Today
After hours$8.33-$0.01 (-0.12%)
Immix Biopharma last closing stock price
MetricPriceDate
Last closeUSD 8.552026-07-30
Immix Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.84%USD 8.802026-07-23
1 month-17.07%USD 10.312026-06-30
3 month-8.06%USD 9.302026-05-01
Year to date+63.48%USD 5.232025-12-31
1 year+210.91%USD 2.752025-07-30
3 year+315.05%USD 2.062023-07-31
Since inception+132.97%USD 3.672021-12-16

Immix Biopharma Financials at a Glance

Market Cap

$608.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$34.98M

EPS (TTM)

-$0.92

P/E Ratio

-9.30

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$8.34

Volume

1,590,592.713

Open

$8.61

Previous Close

$8.32

Daily Range

$8.21 - $8.72

52-Week Range

$1.94 - $12.14

Estimated Earnings Date

Aug 14, 2026

IMMX News

No articles available.

IMMX: Motley Fool Moneyball Superscore

63

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immix Biopharma

Immix Biopharma develops new medicines for rare cancers and immune diseases. Its main therapies aim to help patients with few treatment options. The company focuses on cell therapies and targeted biologic drugs.

What’s in the Medicine Cabinet?

  • NXC-201 (Lead Program): Cell therapy for light chain amyloidosis, a rare blood disorder; in clinical trials. 0% of revenue as company has no sales.
  • IMX-110: Drug in trials for soft tissue sarcoma and solid tumors; targets cancer cells directly. 0% of revenue.
  • IMX-111: Biologic therapy for colorectal cancer; designed to target tumors more precisely. 0% of revenue.
  • IMX-120: Biologic drug for ulcerative colitis and Crohn’s disease, both chronic bowel conditions. 0% of revenue.
  • N-GENIUS Platform: Technology for developing new cell therapies; supports pipeline innovation. 0% of revenue.

Growth Moves: The Expansion Playbook

  • Signed a clinical collaboration with BeiGene in 2024 for combination cancer trials.
  • Expanded NXC-201 clinical trials to 18 sites by July 2025.
  • Secured an $8 million grant from the California Institute for Regenerative Medicine in 2024.
  • Raised $100 million in a public offering in December 2025.
  • Leased new manufacturing space in California in 2024, with a lease through 2033.

What Makes Immix Biopharma Stand Out?

The company targets rare diseases with few existing treatments, focusing on cell therapies. It holds exclusive global rights to its main technology platform and lead drug candidate. Immix Biopharma relies on third-party partners for manufacturing and clinical trials, allowing flexibility and scalability.

Five Things You Need to Know

  • No revenue reported for 2023-2025; remains pre-commercial.
  • Net loss was $29.4 million in 2025, up 36% from 2024.
  • Cash, cash equivalents, and short-term investments totaled $100.4 million at end-2025.
  • Research and development expenses rose 44% to $16.3 million in 2025.
  • Raised over $113 million in capital and grants during 2025.

Bottom Line

Immix Biopharma is a clinical-stage biotech focused on rare disease therapies. The company’s growth depends on advancing its pipeline and securing funding for future development.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

21

CEO

Ilya Rachman, MD, PhD

Website

www.immixbio.com

Headquarters

Los Angeles, CA 90064, US

IMMX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-73.23%

Return on Capital

-28.68%

Return on Assets

-36.51%

Earnings Yield

-10.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$608.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

71.19M

Volume

1.59M

Avg. Volume

1.75M

Financials (TTM)

Gross Profit

-$130.77K

Operating Income

-$36.08M

EBITDA

-$34.56M

Operating Cash Flow

-$32.07M

Capital Expenditure

-$697.70K

Free Cash Flow

-$32.77M

Cash & ST Invst.

$90.58M

Total Debt

$1.04M

Immix Biopharma Performance Analysis

Immix Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Immix Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Immix Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.62-66.3%
20232023-12-31USD -0.8943.0%
20242024-12-31USD -0.76-14.1%
20252025-12-31USD -0.8916.9%
Immix Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-46.7%
Q32025-09-30-9.1%
Q42025-12-31-16.7%
Q12026-03-3135.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$130.77K

N/A

Gross Margin

0.00%

N/A

Market Cap

$608.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$28.98M

N/A

Employees

21

N/A

Net Income

-$10.09M

-122.1%

EBITDA

-$9.96M

-122.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$90.58M

+468.9%

Total Debt

$1.04M

-2.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$912.34K

-7.9%

Short Term Debt

$125.39K

+84.9%

Return on Assets

-36.51%

N/A

Return on Invested Capital

-42.31%

N/A

Free Cash Flow

-$9.86M

-462.5%

Operating Cash Flow

-$9.83M

-483.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZNTLZentalis Pharmaceuticals, Inc.
$4.74-3.66%
MGNXMacroGenics, Inc.
$3.69-2.38%
WHWKWhitehawk Therapeutics Inc
$3.85+0.00%
ORMPOramed Pharmaceuticals Inc.
$4.07-1.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About IMMX

What is the current price of Immix Biopharma?

Immix Biopharma is trading at $8.32 per share.

What is the 52-week range for Immix Biopharma?

Over the past 52 weeks, Immix Biopharma has traded between $1.94 and $12.14.

How much debt does Immix Biopharma have?

As of the most recent reporting period, Immix Biopharma reported total debt of $1.04M.

How much cash does Immix Biopharma have on hand?

Immix Biopharma reported $79.25M in cash and cash equivalents in its most recent financial results.

What is Immix Biopharma’s dividend yield?

Immix Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services